Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6 cell line located in the EU. Other terms of the agreement were not disclosed.
The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies.
Karen King, president of DSM Biologics, said: “The growing number of PER.C6 licensees requires that we expand the possibilities for our licensees to obtain services like cell line generation. We are confident that Bioceros’s excellent experience and service level will provide our European licensees additional options to move their PER.C6 programs forward successfully.”